Antivirals for COVID-19: five questions that must be answered, Pharmaceutical Journal

Furthest ahead is molnupiravir, an oral agent from MSD. Candidates from Pfizer& Roche/Atea not far behind, with further announcements expected in coming weeks. Article looks at whether these antivirals really make a difference, who will get them and how much they will cost.

Source: Current Awareness Service for Health (CASH) - October 22, 2021 Category: Consumer Health News Source Type: news